AR126892A1 - Compuestos de aminopiridina sustituidos como inhibidores de egfr - Google Patents
Compuestos de aminopiridina sustituidos como inhibidores de egfrInfo
- Publication number
- AR126892A1 AR126892A1 ARP220102310A ARP220102310A AR126892A1 AR 126892 A1 AR126892 A1 AR 126892A1 AR P220102310 A ARP220102310 A AR P220102310A AR P220102310 A ARP220102310 A AR P220102310A AR 126892 A1 AR126892 A1 AR 126892A1
- Authority
- AR
- Argentina
- Prior art keywords
- egfr inhibitors
- compound
- pharmaceutically acceptable
- acceptable salt
- aminopyridine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo. Una composición farmacéutica para tratar una enfermedad mediada por proteína quinasa, que comprende un compuesto de cualquiera de las reivindicaciones 1 a 23, o una de sus sales farmacéuticamente aceptables como ingredientes activos. Una composición farmacéutica para inhibir selectivamente al menos un mutante de EGFR en comparación con el EGFR de tipo silvestre, que comprende un compuesto de cualquiera de las reivindicaciones 1 a 23, o una de sus sales farmacéuticamente aceptables como ingredientes activos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237647P | 2021-08-27 | 2021-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126892A1 true AR126892A1 (es) | 2023-11-29 |
Family
ID=85321881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102310A AR126892A1 (es) | 2021-08-27 | 2022-08-26 | Compuestos de aminopiridina sustituidos como inhibidores de egfr |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11981658B2 (es) |
| EP (1) | EP4392415A4 (es) |
| JP (1) | JP2024534169A (es) |
| KR (1) | KR20240052797A (es) |
| CN (1) | CN117980297A (es) |
| AR (1) | AR126892A1 (es) |
| TW (1) | TW202317106A (es) |
| WO (1) | WO2023027518A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120693323A (zh) * | 2023-03-16 | 2025-09-23 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| AR132866A1 (es) * | 2023-06-09 | 2025-08-06 | Yuhan Corp | Derivados de pirimidina / piridina o sales de los mismos y composiciones farmacéuticas que los comprenden |
| CN118955498A (zh) * | 2024-07-25 | 2024-11-15 | 浙江大学 | 一种靶向Tau蛋白的新型PET显像剂及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| WO2004065378A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| ATE458730T1 (de) | 2004-04-13 | 2010-03-15 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal- modulatoren |
| EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| AU2005232745A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| JP5600063B2 (ja) * | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2991977B1 (en) | 2013-05-01 | 2020-07-22 | F.Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| EP3157916B1 (en) * | 2014-06-19 | 2018-12-12 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN106588885B (zh) | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| US11667651B2 (en) * | 2017-12-22 | 2023-06-06 | Hibercell, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019222538A1 (en) | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Aminopyrimidines and aminopyridines as mertk inhibitors and their application in cancer treatment |
| KR102297587B1 (ko) * | 2018-08-07 | 2021-09-06 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN111793031B (zh) | 2019-04-02 | 2021-06-22 | 海创药业股份有限公司 | 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| HRP20241633T1 (hr) * | 2019-06-28 | 2025-02-14 | Chengdu Zenitar Biomedical Technology Co., Ltd. | 2,4-disupstituirani derivat pirimidina, postupak njegove pripreme i njegova uporaba |
| WO2021097326A1 (en) | 2019-11-15 | 2021-05-20 | The University Of North Carolina At Chapel Hill | Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof |
-
2022
- 2022-08-24 TW TW111131849A patent/TW202317106A/zh unknown
- 2022-08-25 CN CN202280062421.XA patent/CN117980297A/zh active Pending
- 2022-08-25 WO PCT/KR2022/012696 patent/WO2023027518A1/en not_active Ceased
- 2022-08-25 JP JP2024513142A patent/JP2024534169A/ja active Pending
- 2022-08-25 KR KR1020247009721A patent/KR20240052797A/ko active Pending
- 2022-08-25 EP EP22861726.2A patent/EP4392415A4/en active Pending
- 2022-08-26 AR ARP220102310A patent/AR126892A1/es unknown
- 2022-08-26 US US17/822,450 patent/US11981658B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4392415A4 (en) | 2025-10-01 |
| TW202317106A (zh) | 2023-05-01 |
| US20230086884A1 (en) | 2023-03-23 |
| CN117980297A (zh) | 2024-05-03 |
| WO2023027518A1 (en) | 2023-03-02 |
| JP2024534169A (ja) | 2024-09-18 |
| EP4392415A1 (en) | 2024-07-03 |
| KR20240052797A (ko) | 2024-04-23 |
| US11981658B2 (en) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| DOP2021000019A (es) | Inhibidores de inflamasoma nlrp3 | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2023000670A1 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| DOP2025000044A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| CL2024002500A1 (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| AR131909A1 (es) | Compuestos macrocíclicos de aminopiridina como inhibidores de egfr | |
| CR20240216A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| AR124975A1 (es) | Compuestos químicos | |
| CO2025001460A2 (es) | Inhibidores de proteína de unión a emopamil y usos de estos | |
| AR133607A1 (es) | Inhibidores de la proteína de unión al emopamilo y usos de estos | |
| CL2021001093A1 (es) | Compuestos, composiciones, y métodos para modular la actividad cdk9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |